We are a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies.
Is CymaBay a good stock to buy?
There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CymaBay Therapeutics stock.
Will CymaBay Therapeutics stock go up?
The 9 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +304.04% increase from the last price of 2.97.
Why did CBAY stock drop?
Shares of CymaBay Therapeutics (NASDAQ:CBAY) fell over 76% today after the company announced that it was halting the development of its lead drug candidate, seladelpar, in primary biliary cholangitis (PBC).25 Nov 2019
Is CBAY a good stock to buy 2021?
CymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.